OptimizeRx Ranked Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

Rhea-AI Summary

OptimizeRx Corp (Nasdaq: OPRX) announced a remarkable 257% revenue growth, attributed to brand acquisition and product adoption, during the recent Deloitte Technology Fast 500 ranking announcement.

CEO William Febbo expressed confidence in the company’s growth trajectory, emphasizing their position in the digital point-of-care sector. The Deloitte award is a recognition of the top 500 fastest-growing tech companies in North America, showcasing OptimizeRx's robust performance from 2017 to 2020.

Positive

• 257% revenue growth due to brand acquisition and product adoption.
• Recognition in Deloitte Technology Fast 500 as a top-growing tech company.

Negative

• None.

Attributes 257% Revenue Growth to Brand Acquisition and Product Adoption

ROCHESTER, Mich., Nov. 23, 2021 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy today announced its inclusion on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. OptimizeRx grew 257% during this period.

OptimizeRx CEO, William Febbo, credits brand acquisition and product adoption with the company’s 257% revenue growth during the measured period. He said, "For the second consecutive year we’ve had the honor to be included on Deloitte’s Technology Fast 500 List. We have steadily positioned the Company for a second stage of accelerated growth capitalizing on the healthcare industry’s paradigm shift to digital point-of-care. With a mature business model, we are confident in the growth trajectory that we have plotted before us which has already resulted in expanded revenues from a growing roster of brands who rely on both our technology solutions and point of care network, the largest in the nation.”

“Each year the Technology Fast 500 shines a light on leading innovators in technology and this year is no exception,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “In the face of innumerable challenges resulting from the pandemic, the best and brightest were able to pivot, reinvent and transform and grow. We celebrate the winning organizations and especially the talented employees driving their success.”

“The pandemic has underscored the urgent need for tech solutions in a variety of areas across health care, fintech, energy tech, entertainment, to name a few, so reliance on innovators like the winners of the Technology Fast 500 is more important than ever,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s audit & assurance practice. “These companies are not only at the cutting edge, transforming the way we do business, but most importantly, recognize the strategic importance of ongoing innovation, especially in the ever-changing world of technology.”

About the 2021 Deloitte Technology Fast 500™
Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.

In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.

About OptimizeRx
OptimizeRx is the best-in-class health technology company enabling care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through a proprietary point-of-care network, connectivity is facilitated via its integrated Therapy Initiation and Persistence Platform. This powerful digital healthcare solutions platform is transforming market and patient access with the life sciences market by unlocking:

• AI-directed, real-time HCP marketing to raise awareness of treatment benefits to give patients a timely start on therapy
• Streamlined communication and processes around therapy initiation to reduce abandonment through simplified enrollment
• Personalized, successful adherence programs to help patients stay on their doctor-recommended course of therapy

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact 
Andy D’Silva, SVP Corporate Finance
adsilva@optimizerx.com

Media Relations Contact 
Maira Alejandra, Media Relations Manager 
malejandra@optimizerx.com

Investor Relations Contact
Ashley Robinson
LifeSci Advisors, LLC
arr@lifesciadvisors.com

FAQ

What caused OptimizeRx's revenue growth?

OptimizeRx attributed its 257% revenue growth to brand acquisition and product adoption.

What recognition did OptimizeRx recently achieve?

OptimizeRx was included in the Deloitte Technology Fast 500 list for significant revenue growth.

How does OptimizeRx's revenue growth impact stock performance?

A strong revenue growth of 257% may positively influence investor confidence and stock performance.

When was the Deloitte Technology Fast 500 announced?

The announcement was made on November 23, 2021.

What is the stock symbol for OptimizeRx?

The stock symbol for OptimizeRx is OPRX.